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BRIEF DEFINITIVE REPORT
        Proteoglycans (PGs) are distributed ubiquitously 
as a component of extracellular matrix (ECM) 
at the cell surface and bear glycosaminoglycans 
(GAGs) such as heparan sulfate (HS) and chon-
droitin sulfate (CS). HSPGs are critically in-
volved in various physiological and pathological 
conditions. One important feature of HSPG is 
the ability to interact with a variety of growth 
factors, cytokines, chemokines, and ECM pro-
teins, thereby regulating wound healing, tissue 
remodeling, hemostasis, and infl  ammation (  1  ). 
Syndecans are the major cell-surface PGs ex-
pressed by virtually all epithelial cells. Syndecan-4 
is a member of the syndecan family and is an 
important constituent of host defense mech-
anisms by acting as a regulatory receptor that 
monitors dynamic changes in ECM composi-
tion and organization during tissue injury and 
remodeling ( 2  –  6  ). However, the molecular mech-
anism by which syndecan-4 regulates complex 
host defense responses remains to be elucidated. 
Osteopontin (OPN) is classifi  ed not only as an 
ECM but also a cytokine and is involved in vari-
ous physiological and pathological conditions 
(  7  –  17  ). OPN function is modulated by protease 
digestion, and the thrombin-cleaved form of 
OPN is critically involved in the pathogen  esis 
of various infl  ammatory disorders (  12, 14  ). Be-
cause thrombin can be activated by various in-
sults, including infection and immune reactions, 
there must be regulatory mechanisms that con-
trol the cleavage of OPN by thrombin. Other-
wise, host defense systems are frequently forced 
to confront proinfl  ammatory insults initiated by 
thrombin-cleaved forms of OPN. There are two 
putative heparin-binding domains (HBDs) within 
OPN, and one domain overlaps the consensus 
thrombin cleavage site within OPN molecules 
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  Osteopontin (OPN) is a T helper type 1 immunoregulatory cytokine that plays a critical 
role in various infl  ammatory disorders. OPN exerts proinfl  ammatory reactions through 
interaction with integrin receptors. OPN function can be modulated by protease digestion. 
However, the molecular mechanisms that regulate OPN function in vivo have not been 
elucidated. There are two putative heparin-binding domains (HBDs) within the OPN 
molecule, which may bind both heparin and heparin-like glycosaminoglycans such as syndecan. 
We show that expression of OPN and syndecan-4 is significantly up-regulated after 
concanavalin-A (ConA) injection. Syndecan-4 binds to one of the HBDs of OPN, which 
overlaps with the thrombin cleavage site of OPN. When OPN is associated with syndecan-4, 
syndecan-4 masks both the thrombin cleavage and the integrin binding sites within OPN. 
Importantly, syndecan-4  –  defi  cient (Syn4KO) mice are more susceptible to hepatic injury, 
and the thrombin-cleaved form of OPN is signifi  cantly elevated in Syn4KO mice as compared 
with wild-type mice after ConA injection. Finally, we demonstrate that administration of 
purifi  ed syndecan-4 protects mice from ConA-induced hepatic injury. Thus, syndecan-4 is a 
critical intrinsic regulator of infl  ammatory reactions via its effects on OPN function and is 
a potential novel therapeutic tool for treating infl  ammatory diseases. 26 SYNDECAN-4 REGULATES OPN-MEDIATED LIVER INJURY | Kon et al.
    RESULTS AND DISCUSSION   
  Specifi  c binding of heparin and syndecan-4 to the HBD 
of OPN 
  We initially examined whether heparin binds to OPN. The 
binding of biotinylated heparin to the full-length form (OPN 
full/glutathione S-transferase [GST]), the amino-terminal half of 
thrombin-cleaved form (OPN N half/GST), and the carboxy-
terminal half of thrombin-cleaved form (OPN C half/GST) 
of human OPN was tested. Heparin bound to   Escherichia 
coli    –  derived OPN full/GST (  Fig. 1 A  ).   In contrast, the same 
heparin preparation failed to bind to both OPN N half/GST 
and OPN C half/GST. OPN is heavily glycosylated in vivo 
(  17  ) and   E. coli    –  derived OPN lacks glycosylation. To exclude 
that the lack of sugar moiety on OPN aff  ects binding of OPN 
to heparin, we prepared the glycosylated form of recombi-
nant OPN from Chinese hamster ovary (CHO) cells. Again, 
heparin bound only to the full-length form of OPN in a dose-
dependent manner (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20071324/DC1). Note that the amino 
acid sequences that correspond to two putative HBDs are 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20071324/DC1) ( 17  ). It is unknown whether HBDs within 
OPN really bind to heparin and HS. Syndecan-4 is known 
to regulate thrombin activity (  18, 19  ), and OPN function is 
regulated by thrombin cleavage (  12, 14, 17, 20  ). Therefore, 
it is of importance to examine whether syndecan-4 can asso-
ciate with OPN and modulate OPN function. In this report, 
we show that one of the HSPGs, syndecan-4, specifically 
binds to the HBD of OPN via HS moiety. Syndecan-4, when 
bound to OPN, masks not only thrombin cleavage but also 
integrin binding sites within OPN molecules, thus regulating 
various OPN functions. The absence of syndecan-4 results in 
the exacerbation of concanavalin-A (ConA)  –  induced hepatic 
injury and augmentation of the production of the thrombin-
cleaved form of OPN, which plays a critical role in hepatic 
tissue injury (  14  ). Importantly, administration of exogenous 
syndecan-4 protects mice from ConA-induced hepatic in-
jury. Thus, we show that syndecan-4 is a critical intrinsic 
regulator of infl  ammatory reactions through the regulation of 
OPN functions. 
    Figure 1.         The specifi  c binding of OPN to heparin and HSPG, a syndecan-4.   (A) Biotinylated heparin binds to the nonglycosylated form of full-
length OPN. Plates were precoated with recombinant OPN, derived from   E. coli  , as indicated. (B) Biotinylated heparin binds to the synthetic peptide 
  corresponding to one of two putative HBDs of OPN. (C) The binding of 3     g/ml of recombinant Syn4Ig to the plate precoated with either the full-length 
or thrombin-cleaved form of human OPN (OPN or T-OPN, respectively), or 10     g/ml of the full-length form of mouse OPN (mOPN). In some experiments, 
the HS or CS chain of Syn4Ig was digested by either HSase or CSase, respectively. Data are presented as means   ±   SEM. **, P   <   0.005. (D) The interaction 
of the native form of OPN and syndecan-4. The ability of human cell lines to secrete OPN, syndecan-4, and HS were listed. NRC-12 or OPN/Namalwa cells 
were stimulated with PMA. Culture supernatants were applied to the affi  nity column coupled with anti  –  syndecan-4 antibody, anti-OPN antibody, or 
control antibody. After washing, eluates were applied to SDS-PAGE analysis, transferred to membranes, and immunoblotted (IB) with either anti-OPN or 
anti  –  syndecan-4 antibody. ND, not detected.     JEM VOL. 205, January 21, 2008  27
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OPN and syndecan-4 proteins were immuno  blotted in the 
bound fraction from the anti  –  syndecan-4 antibody  –  coupled 
column but not from the control column, indicating the pres-
ence of association between OPN and syndecan-4. Culture 
supernatants were also applied to the affi   nity column coupled 
with anti-OPN antibody. The syndecan-4 was immunoblotted 
in the bound fraction derived from NRC-12 cells but not from 
OPN/Namalwa cells (  Fig. 1 D  ). In addition, we confi  rmed 
the association of OPN and syndecan-4 by using genetically 
manipulated CHO cells transiently expressing human OPN, 
syndecan-4, or both OPN and syndecan-4 (Fig. S4, available 
at http://www.jem.org/cgi/content/full/jem.20071324/DC1). 
We also found that, like heparin, the binding of Syn4Ig 
was specifi  c to the one of two putative HBDs of OPN that 
overlaps the thrombin cleavage site (Fig. S5). Thus, the phys-
iological association of HBDs of OPN and HS moiety of 
syndecan-4 exists, and the biological signifi  cance of this asso-
ciation remains to be elucidated. 
  Syndecan-4 modulates OPN functions by masking 
functional domains of OPN 
  We thus examined whether the association of OPN and syn-
decan-4 modulates the availability of OPN to thrombin and/
or its receptors. OPN proteins were mixed with either human 
IgG or Syn4Ig. Addition of thrombin resulted in the signifi  -
cant reduction of full-length OPN levels in OPN preparation 
when mixed with human IgG. However, when OPN was 
mixed with Syn4Ig, OPN was resistant to thrombin digestion 
(  Fig. 2 A  ).   Because the binding domain of syndecan-4 to 
OPN overlaps the thrombin cleavage site, the thrombin resis-
tance may be achieved through the masking of the thrombin-
cleaved site by syndecan-4. Syndecan-4 was originally detected 
in microvascular endothelial cells as an antithrombin binding 
molecule (  19, 26  ). Antithrombin is a plasma serine protease 
inhibitor and, thus, inhibits thrombin activity by forming a 
  165  YGLRSKSKKF  174  , which contains thrombin cleavage site 
  168  R/S  169  , and   298  DKHLKFRI  305  , which exists in OPN C 
half/GST (Fig. S1). Heparin binds to YGLRSKSKKF and 
VVYGLRSKSKKFRR, but not to KSKEEDKHLKFRISHE 
and IPVKQADSGSSEEKQ (  Fig. 1 B  ). Thus, heparin binds 
only to one of two putative HBDs of OPN, which contains 
the thrombin cleavage site. Other than heparin within mast 
cells, a major form of heparin-like GAG exists as HS in vivo, 
and syndecan is one of the major transmembrane molecules 
that possesses HS (  1, 21  ). Therefore, we examined whether 
syndecan-4 binds to OPN in vitro. To do this, we prepared a 
soluble form of human syndecan-4 in which the extracellular 
portion of syndecan-4 is fused to the Fc portion of human 
IgG1 (Syn4Ig). The structural relationship between HS moiety 
and Syn4Ig is schematically depicted in Fig. S3. Syn4Ig bound 
to the full-length form but not to the thrombin-cleaved form 
of human OPN (  Fig. 1 C  ). It should be remembered that the 
majority of GAG chains added to the core proteins of synde-
can are of the HS type; however, syndecan-4 is also modi-
fi  ed by CS chains (  22  ). Basic fi  broblast growth factor bound 
only to the HS chains of syndecan, whereas midkine bound 
to both the HS and CS chains (  23  –  25  ). Therefore, we asked 
whether the binding of syndecan-4 to OPN is dependent on 
HS or CS chains. Syn4Ig was digested with either heparitinase 
(HSase) and/or chondroitinase ABC (CSase). HSase-treated, 
but not CSase-treated, Syn4Ig lost its binding to OPN, indi-
cating that the HS chain of syndecan-4 is involved in its bind-
ing to OPN. Note that Syn4Ig bound not only to human but 
also to mouse OPN (  Fig. 1 C  ). 
  We further tested whether the interaction of OPN and 
syndecan-4 occurs under physiological conditions. We prepared 
two human cell lines, OPN/Namalwa and NRC-12, that pro-
duce either OPN alone or OPN and syndecan-4, respectively. 
NRC-12 culture supernatants were applied to the affi   nity   column 
coupled with either anti  –  syndecan-4 antibody or control IgG. 
    Figure 2.         The masking of functional domains of OPN by syndecan-4.   (A) OPN becomes less sensitive to thrombin digestion when bound by 
syndecan-4. Recombinant OPN (50     l of 3     g/ml) was mixed with either 50     l of human IgG1 (hIgG) or 6     g/ml Syn4Ig. The mixture was subjected to 
thrombin digestion (2 U/ml) for 37  °  C for 30 min. The full-length form of OPN was measured using ELISA. Note that this ELISA is unable to detect thrombin-
cleaved OPN. (B) OPN recognition by integrin receptors is inhibited by syndecan-4. The binding of CHO cells to OPN is RGD dependent. The binding of 
CHO cells to either precoated OPN alone or OPN together with Syn4Ig was examined. (C) The binding of CHO cells expressing     4 integrin (   4/CHO)  to 
OPN or OPN bound by syndecan-4 was examined in the presence or absence of 100     g/ml GRGDS or 10    g/ml  anti –    4 integrin antibody. Data are 
presented as means   ±   SEM. *, P   <   0.05; **, P   <   0.005.     28 SYNDECAN-4 REGULATES OPN-MEDIATED LIVER INJURY | Kon et al.
performed in the presence of GRGDS peptide, thus allow-
ing the binding of     4/CHO cells to OPN to be     4 integrin 
dependent. As expected, the binding of     4/CHO cells to 
OPN was specifi  cally inhibited not only by anti  –      4 integrin 
antibody but also by syndecan-4 (  Fig. 2 C  ). It is known that 
OPN,     v    3, and     4    1 (also known as very late antigen 4) 
integrins are involved in recruitment and cell adhesion of in-
fl  ammatory cells (  7, 10, 12, 14, 15, 17  ), and it is likely that 
the association of syndecan-4 and OPN may result in the in-
hibition of integrin-mediated infl  ammation. It should be re-
membered that OPN also putatively binds and mediates cell 
migration through CD44 (  7, 10, 17  ). Thus, it is of interest in 
future studies to test whether syndecan-4 regulates the inter-
action of OPN and CD44. 
  Both OPN and syndecan-4 expression are up-regulated in a 
mouse model of ConA-induced hepatic injury 
  To investigate whether the described scenario operates 
in vivo, we examined the role of syndecan-4 in ConA-in-
duced hepatic injury in mice. As expected, both plasma 
OPN and alanine aminotransferase (ALT) levels were sig-
nifi  cantly elevated after ConA injection (  Fig. 3 A  ).   Because 
antibodies against mouse syndecan-4 and HS are com-
mercially available, we constructed a sandwich ELISA to 
measure mouse syndecan-4. Plasma syndecan-4 levels were 
elevated after ConA injection (  Fig. 3 B  ). We also noted that 
syndecan-4 gene expression in the liver was signifi  cantly 
up-regulated at 2 h and persisted up to 12 h after ConA in-
jection (  Fig. 3 C  ). 
covalent complex with thrombin in a 1:1 ratio. Importantly, 
after binding to syndecan-4 in vivo, antithrombin exhibits a 
500-fold increase of its thrombin inhibitory activity (  27  ). 
Therefore, it is likely that in vivo syndecan-4 regulates forma-
tion of thrombin-cleaved OPN by masking the thrombin 
cleavage site of OPN and/or inhibiting thrombin activity via 
association with the antithrombin molecule. 
  OPN can bind to integrin receptors in at least two ways. 
First, a classical integrin binding domain,   159  RGD  161  , within 
the OPN molecule exists close to the consensus thrombin 
cleavage site,   168  R/S  169   (  17  ). Therefore, the recognition of 
OPN by an RGD-recognizing integrin receptor such as     v    3 
can be blocked when OPN is bound by syndecan-4. The 
binding of CHO cells to OPN was specifi  cally inhibited 
by GRGDS peptides, confi  rming that this binding is RGD 
dependent. The binding of CHO cells to OPN was signifi  -
cantly inhibited when OPN was mixed with syndecan-4 but 
not with human IgG (  Fig. 2 B  ). Note that OPN binds to the 
plates comparably well in the presence or absence of Syn4Ig 
in cell adhesion assays (Fig. S6, available at http://www.jem
.org/cgi/content/full/jem.20071324/DC1), indicating that 
Syn4Ig competes for CHO cell adhesion to plate-coated 
OPN rather than preventing OPN from binding to the plates. 
Second, the   162  SVVYGLR  168   domain, which can be recog-
nized by     4    1 integrin (  12, 14  ), exists also very close to the 
thrombin cleavage site (  17  ). We therefore tested whether the 
binding of CHO cells expressing     4    1 integrin (    4/CHO) 
to OPN can be inhibited by Syn4Ig. Because CHO cells 
express an RGD-recognizing receptor, a binding assay was 
    Figure 3.         The augmented expression of OPN and syndecan-4 in a mouse model of fulminant hepatitis.   C57BL/6 mice were intravenously 
injected with ConA (  n   = 3). (A) The plasma levels of ALT and OPN after ConA injection. (B) The plasma levels of syndecan-4 after ConA injection. (C) RT-PCR 
analysis and real-time PCR analysis of syndecan-4 expression in liver after ConA injection. Data are presented as means   ±   SEM.   JEM VOL. 205, January 21, 2008  29
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control mice (  Fig. 4 C  ), indicating that levels of the thrombin-
cleaved form of OPN correlate well with the degree of in-
fl  ammation and tissue injury as previously reported (  28  ). The 
specifi  city of ELISA used for the detection of the thrombin-
cleaved form of mouse OPN is shown in Fig. S7 (available at 
http://www.jem.org/cgi/content/full/jem.20071324/DC1). 
  To further test whether OPN is really responsible for the 
exacerbation of infl  ammation after ConA injection in Syn4KO 
mice, mice were treated with a neutralizing antibody raised 
against the cleaved form of OPN (M5) (  12, 14  ). Syn4KO 
mice treated with anti-OPN (M5) antibody showed signifi  -
cant amelioration of ConA-induced hepatic injury as judged 
by the level of plasma ALT and liver histology (  Fig. 4 D  ). 
  Administration of exogenous recombinant syndecan-4 
protects mice from ConA-induced hepatic injury 
  The fi  nal issue we addressed was whether the exogenous pu-
rifi  ed syndecan-4 can protect mice from ConA-induced he-
patic injury. Syndecan-4  –  injected mice were protected from 
hepatic injury, as refl  ected by reduced levels of ALT and 
IFN-     after ConA injection compared with those in control 
mice (  Fig. 5 A  ).   It has been previously shown that OPN is 
  Absence of syndecan-4 exacerbates ConA-induced acute 
hepatic injury and augments production of the thrombin-
cleaved form of OPN 
  If syndecan-4 plays a critical role in the regulation of OPN 
cleavage by thrombin in vivo, the syndecan-4 defi  ciency 
should result in the exacerbation of hepatic injury after ConA 
injection. Under the condition in which control mice devel-
oped mild hepatic injury after ConA injection, syndecan-4  – 
defi  cient (Syn4KO) mice developed signifi  cantly severe hepatic 
injury, as refl  ected by the elevation of ALT and aspartate amino-
transferase (AST) levels (  Fig. 4 A  ).   This fi  nding correlated 
well with the histology in which control mice showed mi-
nor hepatic necrosis, whereas there was massive necrosis in 
Syn4KO mice (  Fig. 4 B  ). Consistent to these fi  ndings, the sur-
vival rate of mice treated with ConA was signifi  cantly reduced 
in Syn4KO mice as compared with control mice. Note that 
plasma levels of the full-length form of OPN were not diff  erent 
between wild-type and Syn4KO mice after ConA injection, 
indicating that the absence or presence of syndecan-4 did not 
infl  uence the induction of OPN expression itself. However, 
importantly, thrombin-cleaved OPN levels were elevated in 
Syn4KO mice after ConA injection as compared with those in 
    Figure 4.         The high susceptibility of Syn4KO mice to ConA-induced hepatic injury.   (A) The plasma levels of ALT and AST in wild-type (Cont) and 
Syn4KO mice at 12 h after ConA injection (  n   = 6 per each group). (B) Representative histology of liver sections stained by H-E 12 h after ConA injection, 
and the survival curve after ConA injection (  n   = 8 and 13 wild type and Syn4KO, respectively). Dotted lines indicate the area of liver degeneration. The 
degenerative area per liver section was quantifi  ed by using ImageJ (  n   = 3 per each group). Bar, 200     m. (C) The plasma levels of full-length and thrombin-
cleaved OPN in wild-type (Cont) and Syn4KO mice at 12 h after ConA injection (  n   = 4 and 6 wild type and Syn4KO, respectively). (D) The attenuation of 
ConA-induced hepatic injury in Syn4KO mice by anti-OPN (M5) antibody treatment (  n   = 5 per group). Syn4KO mice were intraperitoneally treated with 
M5 antibody and control normal rabbit IgG (Cont Ig; 400     g/head) at 15 h before ConA injection. Plasma ALT levels and representative histology (HE) are 
shown. Degenerative area per liver section was quantifi  ed by using ImageJ (  n   = 5 per each group). Data are presented as means   ±   SEM. *, P   <   0.05; 
**, P   <   0.005. Bar, 500    m.   30 SYNDECAN-4 REGULATES OPN-MEDIATED LIVER INJURY | Kon et al.
the production of the thrombin-cleaved form of OPN, which 
favors the exacerbation of infl  ammatory reaction and tissue 
injury. Meanwhile, syndecan-4 acts as a negative regulator of 
infl  ammatory responses by binding to HBDs of OPN, thus 
interfering with integrin-mediated cell adhesion and migration 
and/or masking the thrombin cleavage site of OPN, leading 
to the inhibited formation of the thrombin-cleaved form of 
OPN. Further research is needed to determine whether OPN 
function is also regulated by other HSPGs such as syndecan-
1, -2, and -3 and glypican. HSPG deserves further investiga-
tion as a novel therapeutic tool for various infl  ammatory diseases. 
  MATERIALS AND METHODS 
  OPN and syndecan-4 preparations.     The three human OPN complemen-
tary DNAs (cDNAs) were inserted into pGEX-4T vector (GE Healthcare) in 
the same reading frame as the carrier gene GST and were transformed in   E. coli   
JM109 cells. Thus, three unglycosylated human OPN/GST fusion proteins 
were produced: OPN full/GST (M1-N314), OPN N half/GST (M1-R168), 
and OPN C half/GST (K170-N314). These proteins were purifi  ed as described 
previously (  29  ). To prepare the glycosylated forms of OPN (OPN/CHO and 
OPN N half/CHO), the full-length human and mouse OPN and OPN N half 
cDNAs were inserted into pcDNA3 (Invitrogen) and transfected to CHO-K1 
cells with Lipofectamine 2000 (Invitrogen). The glycosylated form of human 
OPN was purifi  ed with a formyl-cellulofi  ne column (Seikagaku Kogyo) 
coupled with anti-OPN (O-17) antibody (Immuno-Biological Laboratories 
involved in cell adhesion, cell migration, and infl  ammation 
via integrin receptors (  7, 10, 12, 14, 15, 17  ). Therefore, we 
tested whether administration of syndecan-4 would inhibit 
OPN-mediated infl  ammatory responses by fl  ow cytometry. 
The infi  ltration of infl  ammatory cells into liver tissues in 
ConA-injected mice was signifi  cantly inhibited by the ad-
ministration of exogenous syndecan-4 (  Fig. 5 B  ). Infi  ltrated 
leukocytes and macrophages/Kupff  er cells were defi  ned by 
the expression of CD45 and F4/80, respectively. Neverthe-
less, hepatic necrosis in histology was signifi  cantly reduced by 
the administration of syndecan-4 (  Fig. 5 C  ). 
  Thus, our report reveals a novel role of HSPG in protec-
tion against OPN-mediated hepatic injury. One of the major 
HSPGs, syndecan-4 is a critical intrinsic regulator of infl  am-
matory reactions in vivo by regulating various OPN functions. 
We identifi  ed the primary amino acid sequence within a puta-
tive HBD within OPN, which interacts with the HS moiety 
of syndecan-4. The putative in vivo role of syndecan-4 in 
OPN-mediated infl  ammatory reactions is schematically shown 
in   Fig. 5 D  . Initial infl  ammation insult induces the up-regu-
lation of OPN and syndecan-4 expression, and activa  tion of 
thrombin at the site of insult. OPN induced the migration 
and cell adhesion of infl  ammatory cells through interaction with 
integrins. Thrombin cleaves OPN specifi  cally and augments 
    Figure 5.         Exogenous syndecan-4 protects mice from ConA-induced hepatic injury.   (A) Exogenous syndecan-4 protects mice from ConA-induced 
hepatic injury, as judged by plasma ALT levels and plasma IFN-     levels at 12 h after ConA injection. Normal human IgG (Cont Ig) was used as a control 
IgG (  n   = 10 per each group). (B) Liver-infi  ltrating leukocytes were prepared from Syn4Ig- or control normal human IgG (Cont Ig)  –  treated mice at 12 h 
after ConA injection (  n   = 5 per group). The number of CD45-positive leukocytes and F4/80-positive macrophages was determined by fl  ow cytometry. 
(C) Representative histology of liver sections stained by H-E at 24 h after ConA injection. The degenerative area per liver section was quantifi  ed by using 
ImageJ (  n   = 4 per each group). Data are presented as means   ±   SEM. *, P   <   0.05; **, P   <   0.005. Bar, 500     m. (D) Schematic illustration of the in vivo role of 
syndecan-4 in OPN-mediated infl  ammatory reactions.     JEM VOL. 205, January 21, 2008  31
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to syndecan-4, NRC-12 cells and OPN/Namalwa cells, stimulated with 
PMA for 30 min in serum-free medium, were cultured for an additional 48 h 
without PMA. The supernatant of NRC-12 cells was applied to an anti  – 
syndecan-4 antibody  –  coupled formyl-cellulofi  ne column and washed exten-
sively. A rabbit IgG  –  coupled formyl-cellulofi  ne column was used as a control 
column. Elute fraction with 0.2 M glycine-HCl, pH 2.5, was immediately 
neutralized and electrophoresed through 12% SDS-PAGE gel and probed 
with anti-OPN (1B20) or anti  –  syndecan-4 antibody. The supernatants of 
NRC-12 and OPN/Namalwa cells were also applied to an anti-OPN anti-
body (O-17; IBL)  –  coupled formyl-cellulofi  ne column and Western blotted. 
The supernatants obtained from CHO cells, transiently transfected with OPN 
alone, syndecan-4 alone, or both OPN and syndecan-4 cDNA, were also 
tested for the presence of association between OPN and syndecan-4. 
  Thrombin treatment of OPN.     50     l of 3     g/ml hOPN/CHO protein 
was mixed with either 50     l of human IgG1 (hIgG) or 6     g/ml Syn4Ig and 
incubated for 1 h at 37  °  C, then digested with 2 U of thrombin for 30 min. 
  Cell adhesion test.     The 96-well plates were precoated with 10     g/ml 
OPN/CHO protein in the presence or absence of 20     g/ml Syn4Ig over-
night at 4  °  C, followed by treatment with 0.5% BSA in TBS for 1 h at room 
temperature. Cells were suspended in DMEM containing 0.25% BSA, and 
200   μ  l of cell suspension (at a cell density of 5   ×   10  4   cells per well) was ap-
plied to 96-well plates and incubated for 1 h at 37  °  C. The medium was re-
moved from the plates, and all wells were washed twice. The adherent cells 
were fi  xed and stained by 0.5% crystal violet in 20% methanol for 30 min. 
All wells were rinsed three times with water, and adherent cells were then 
lysed with 20% acetic acid. The resulting supernatants from each well were 
analyzed by an immunoreader (Immuno Mini NJ-2300; Nolge Nunc Inter-
national), and the absorbance at 590 nm was measured to determine the 
relative number of cells adhered to wells. The binding of cells to OPN was 
expressed as 100%. 
  ELISA.     OPN, human syndecan-4 (IBL), and IFN-     (BD Biosciences) con-
centrations were measured by using ELISA kits as specifi  ed by the manufac-
turers. The plasma level of mouse syndecan-4 was measured by using a 
ELISA system, which was established using 10     g/ml of rabbit anti  –  mouse 
syndecan-4 antibody (IBL) for capture antibody and 3     g/ml of biotinylated 
anti-HS antibody (Seikagaku Kogyo) for detection antibody. Purifi  ed mouse 
syndecan-4 Ig was used for standard. The thrombin-cleaved form of mouse 
OPN was detected by ELISA obtained from IBL. The detailed information 
on this ELISA for the thrombin-cleaved form of OPN is shown in Fig. S7. 
  Induction of ConA-induced liver injury in mice.     C57BL/6 mice were 
injected intravenously with 10 mg ConA (Sigma-Aldrich) per kilogram of 
body weight, dissolved in pyrogen-free PBS. In some experiments, 150     g 
Syn4Ig or human IgG was administered to mice intraperitoneally 15 h be-
fore ConA challenge. Liver damage was evaluated by measuring the serum 
activity of ALT and AST by using a standard clinical autoanalyzer (DRI-
CHEM 5500V; Fujifi  lm). 
  Histology.     Livers were harvested at various times after ConA injection. 
All specimens were fi  xed in 10% buff  ered formalin and embedded in paraffi   n. 
Sections were cut and stained with hematoxylin and eosin (H-E). Light 
microscopy was performed to assess liver injury. Necrotic areas were mea-
sured in each section by using ImageJ (version 1.37; National Institutes of 
Health), followed by calculation of the necrotic area per section. For each 
tissue, data were obtained using at least three high power fi  elds (  ×  100). 
  Flow cytometry.     Liver-infi  ltrating leukocytes were isolated as previously 
described (  14  ). In brief, livers were minced after a few minutes of perfusion, 
pressed through a stainless steel mesh, and suspended in PBS. After washing, 
cells were resuspended in 33% Percoll solution and centrifuged at 2,000 rpm 
for 15 min to remove liver parenchymal cells. The pellet was treated with 
red blood cell lysis solution, washed with PBS, and resuspended in 10% 
FCS-DMEM. The numbers of leukocytes and macrophages were   determined 
Co., Ltd. [IBL]), as described previously (  30  ). Mouse OPN was purifi  ed with a 
formyl-cellulofi  ne column coupled with rabbit anti  –  mouse OPN (M3) antibody 
raised against   155  KSRSFQVSDEQYPDATDE  172   (IBL). The cDNA for human 
syndecan-4 and the extracellular domain of human syndecan-4 (M1-E145) 
were PCR amplifi  ed from NRC-12 cells, and the cDNA for the extracellular 
domain of mouse syndecan-4 (M1-R143) was from B16-BL6 mouse mela-
noma cells using the following primers: human syndecan-4, 5    -TGCG-
GATCCGGTGCCATGGCCCCCGCCCGT-3     (sense) and 5   -TGGCTC-
GAGT  CA  CGCGTAGAACTCATTGGT-3     (antisense); human syndecan-4 
(M1-E145), 5    -TGCAAGCTTGGTGCCATGGCCCCCGCCCGT-3     
(sense) and 5    -TTGGGATCCTCCGTTCTCTCAAAGATGTT-3     (anti-
sense); and mouse syndecan-4 (M1-R143), 5    -AAAGAATTCGAAGCCAT-
GGCGCCTGCCTGC-3     (sense) and 5   -GTCGGATCCCTCTCAAAGAT-
GTTGCTG-3     (antisense). The amplifi  ed product of syndecan-4 was cloned 
into pcDNA3.1. The products of the extracellular domain of syndecan-4 were 
fused with a Fc portion of human IgG1 (Syn4Ig), cloned into pcDNA3.1, and 
transfected to CHO-K1 suspension culture cells with Lipofectamine 2000. 
Syn4Ig was purifi  ed by using protein A column chromatography. 
  Reagents and cell lines.     Thrombin and PMA were obtained from Sigma-
Aldrich. Human renal cell carcinoma cell lines (NRC-12; IBL) and human 
B lymphocyte lines of Burkitt lymphoma origin (Namalwa; American Type 
Culture Collection) were cultured in TIL medium (IBL) supplemented with 
10% FCS. The Namalwa cells were stably transfected with OPN cDNA and 
were referred to as OPN/Namalwa. CHO cells were also transfected with 
OPN alone, syndecan-4 alone, or both OPN and syndecan-4 cDNA. CHO-
K1 (Cell Resource Center for Biomedical Research, Tohoku University) 
and CHO-K1 suspension culture (RIKEN Cell Bank) cells were cultured 
in DMEM/nutrient mixture F-12 (Wako) supplemented with 5% FCS. 
NIH3T3 and B16-BL6 (Cell Resource Center for Biomedical Research, 
Tohoku University) were cultured in DMEM supplemented with 5% FCS. 
Antibodies used to detect human OPN (1B20) and syndecan-4 in the Western 
blot analysis were purchased from IBL. Anti  –      4 integrin (P1H4) antibody 
was obtained from Chemicon. Rabbit antibody (M5) specifi  cally recogniz-
ing the cryptic epitope within mouse OPN molecules, which is exposed by 
thrombin cleavage, was obtained from IBL and used to neutralize the func-
tion of the thrombin-cleaved form of OPN (  12, 14  ). 
  Animals.     6  –  8-wk-old C57BL/6 mice were obtained from Japan SLC. 
  Syndecan-4 KO mice (  3  ), backcrossed   >  10 times into the C57BL/6 back-
ground, were obtained from the Center for Animal Resources and Develop-
ment. These animals were maintained in specifi  c pathogen-free conditions 
in the animal facility of the Laboratory of Animal Experiment for Disease 
Model (Institute for Genetic Medicine, Hokkaido University). All animal 
experiments were in accordance with the guidelines of an institutional com-
mittee at Hokkaido University. 
  Enzyme treatment of syndecan-4.     100     g Syn4Ig was dialyzed against a 
1:1 mixture of 0.1 M sodium acetate buff  er, pH 7, and 10 mM calcium ace-
tate, and digested with 20 mU HSase (Seikagaku Kogyo), with 85 mU CSase 
(Sigma-Aldrich), or with both enzymes at 37  °  C for 15 h. 
  OPN binding to heparin and syndecan-4.     OPN proteins or synthetic 
peptides were coated onto a 96-well plate at various concentrations at 37  °  C 
for 1 h, then blocked with 0.1% BSA in Tris-buff  ered saline (TBS) contain-
ing 0.05% NaN3 at 37  °  C for at least 1 h The plates were washed two times 
with TBS and incubated with either 10     g/ml of biotinylated heparin or 
10     g/ml Syn4Ig at 37  °  C for 1 h After a further three washes, a 1:5,000 
dilution of peroxidase-conjugated streptavidin (Jackson ImmunoResearch 
Laboratories) for biotinylated heparin or peroxidase-conjugated anti  –  human 
IgG (Jackson ImmunoResearch Laboratories) for Syn4Ig were added to each 
well at room temperature for 30 min. Bound protein was quantifi  ed by 
a colorimetric assay using 3,3,5,5-tetramethylbenzidine solution (Thermo 
Fisher Scientifi  c) as a substrate for 15 min at room temperature. Plates were 
read at a wavelength of 450 nm. To evaluate endogenous binding of OPN 32 SYNDECAN-4 REGULATES OPN-MEDIATED LIVER INJURY | Kon et al.
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sciences) and F4/80 (Serotec), respectively. 
  Analysis of messenger RNA (mRNA) expression.     Total RNA from 
livers was extracted by TRI  zol   (Invitrogen). The following primers were 
used: G3PDH, 5    -ACCACAGTCCATGCCATCAC-3     (sense) and 5    -TCC-
ACCACCCTGTTGCTGTA-3     (antisense); and syndecan-4, 5    -ATTC-
GAGAGACAGAGGTCATC-3     (sense) and 5    -CTCTGAGGGGACAC-
GGATGCC-3     (antisense). Quantitative real-time PCR analysis of mRNA 
expression was also performed with LightCycler Fast Start DNA Master 
SYBR Green I Systems (Roche). The expression of mRNA was calcu-
lated by LightCycler software (version 3; Roche). Data were standardized 
by G3PDH. 
  Statistical analysis.     Data are presented as means   ±   SEM and are representa-
tive of at least three independent experiments. Signifi  cant diff  erences be-
tween experimental groups in the adhesion test, thrombin-resistance test, and 
ConA-induced hepatitis model were analyzed using the Student  ’  s   t   test. 
Diff  erences were considered to be signifi  cant when P   <   0.05 (*) or 0.005 (**). 
  Online supplemental material.     Fig. S1 shows the structure of OPN. Fig. S2 
shows the binding of heparin to the full-length form of OPN. Fig. S3 shows 
the structure of syndecan-4 and Syn4Ig. Fig. S4 shows the association between 
OPN and syndecan-4 in the supernatant of CHO transfectant cells. Fig. S5 
shows the binding of Syn4Ig to the HBD of OPN. Fig. S6 shows the bind-
ing of OPN to plates in the presence or absence of Syn4Ig. Fig. S7 shows the 
specifi  city of the ELISA system for detection of the thrombin-cleaved form 
of mouse OPN. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20071324/DC1. 
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